NZ600160A - Methods and compositions for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Info

Publication number
NZ600160A
NZ600160A NZ600160A NZ60016010A NZ600160A NZ 600160 A NZ600160 A NZ 600160A NZ 600160 A NZ600160 A NZ 600160A NZ 60016010 A NZ60016010 A NZ 60016010A NZ 600160 A NZ600160 A NZ 600160A
Authority
NZ
New Zealand
Prior art keywords
kidney injury
injury markers
transmembrane glycoprotein
glycoprotein nmb
renal
Prior art date
Application number
NZ600160A
Other languages
English (en)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of NZ600160A publication Critical patent/NZ600160A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ600160A 2009-11-07 2010-11-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure NZ600160A (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US25913609P 2009-11-07 2009-11-07
US25914509P 2009-11-07 2009-11-07
US25915209P 2009-11-07 2009-11-07
US25914809P 2009-11-07 2009-11-07
US25915909P 2009-11-07 2009-11-07
US25916009P 2009-11-07 2009-11-07
US25913709P 2009-11-07 2009-11-07
US25913909P 2009-11-07 2009-11-07
US25913509P 2009-11-07 2009-11-07
US25916109P 2009-11-07 2009-11-07
US25916209P 2009-11-07 2009-11-07
US25915609P 2009-11-07 2009-11-07
US25915109P 2009-11-07 2009-11-07
US25915509P 2009-11-07 2009-11-07
US25915709P 2009-11-07 2009-11-07
US25915309P 2009-11-07 2009-11-07
US25914709P 2009-11-07 2009-11-07
US28592809P 2009-12-11 2009-12-11
US28592909P 2009-12-11 2009-12-11
US32072310P 2010-04-03 2010-04-03
US34655110P 2010-05-20 2010-05-20
US34654710P 2010-05-20 2010-05-20
PCT/US2010/055721 WO2011057138A1 (en) 2009-11-07 2010-11-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
NZ600160A true NZ600160A (en) 2014-05-30

Family

ID=43970376

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ600160A NZ600160A (en) 2009-11-07 2010-11-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624614A NZ624614A (en) 2009-11-07 2010-11-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ624614A NZ624614A (en) 2009-11-07 2010-11-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Country Status (9)

Country Link
EP (2) EP3153863B1 (cg-RX-API-DMAC10.html)
JP (2) JP2013510321A (cg-RX-API-DMAC10.html)
CN (2) CN102711827B (cg-RX-API-DMAC10.html)
AU (2) AU2010314999B2 (cg-RX-API-DMAC10.html)
CA (1) CA2779905A1 (cg-RX-API-DMAC10.html)
EA (1) EA201290195A1 (cg-RX-API-DMAC10.html)
MX (1) MX2012005210A (cg-RX-API-DMAC10.html)
NZ (2) NZ600160A (cg-RX-API-DMAC10.html)
WO (1) WO2011057138A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013023233A1 (en) * 2011-08-12 2013-02-21 Alfred Health Method for diagnosis, prognosis or treatment of acute coronary syndrome (acs) comprising measurement of plasma concentration of macrophage migration inhibitory factor (mif)
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EA201790696A1 (ru) * 2014-10-20 2017-10-31 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
EP3395355B1 (en) 2015-12-18 2026-03-04 Talengen International Limited Plasminogen for use in treating cervical erosion
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
CN107345968A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CN108210893A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肾纤维化的药物及其用途
US11353465B2 (en) 2017-01-12 2022-06-07 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
EP4071480A1 (en) * 2021-04-09 2022-10-12 Fundació Ace. Institut Català de Neurociències Aplicades Cerebrospinal fluid biomarker for alzheimer's disease
WO2024040225A2 (en) * 2022-08-19 2024-02-22 The Johns Hopkins University Diagnosis and treatment of acute kidney injury
CN122297637A (zh) * 2025-08-25 2026-06-30 北京大学第一医院(北京大学第一临床医学院) 跨膜糖蛋白nmb胞外域在治疗和改善急性肾损伤中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP2007078705A (ja) * 1997-04-04 2007-03-29 Seikagaku Kogyo Co Ltd ヘパラン硫酸の定量方法及び定量キット
IL143892A0 (en) * 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
EP1282823B1 (en) * 2000-05-17 2014-05-07 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Proteolytic enzymes for the diagnosis of kidney disorders
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
US7560244B2 (en) * 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
DE602005022928D1 (de) * 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
EP1808694A1 (en) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
WO2008133641A2 (en) * 2006-10-11 2008-11-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
JP2008118915A (ja) * 2006-11-10 2008-05-29 Kazuto Nishio 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
US7842472B2 (en) * 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
WO2010048346A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8460884B2 (en) * 2008-11-05 2013-06-11 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Use of hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a biomarker for renal injury or renal disease

Also Published As

Publication number Publication date
HK1214864A1 (zh) 2016-08-05
AU2014224137A1 (en) 2014-10-02
EP2496258B1 (en) 2016-11-02
EP3153863B1 (en) 2020-04-01
EP3153863A1 (en) 2017-04-12
JP2017026627A (ja) 2017-02-02
CN102711827A (zh) 2012-10-03
CA2779905A1 (en) 2011-05-12
HK1170955A1 (zh) 2013-03-15
CN104914247A (zh) 2015-09-16
NZ624614A (en) 2015-10-30
AU2010314999A1 (en) 2012-06-14
CN102711827B (zh) 2015-05-20
JP6609533B2 (ja) 2019-11-20
WO2011057138A1 (en) 2011-05-12
CN104914247B (zh) 2018-04-17
JP2013510321A (ja) 2013-03-21
MX2012005210A (es) 2012-08-03
EA201290195A1 (ru) 2012-12-28
EP2496258A4 (en) 2013-06-26
AU2010314999B2 (en) 2014-06-26
EP2496258A1 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592365A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ700695A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594771A (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630621A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598034A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608384A (en) Biomarkers of renal injury
EP2813848A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598741A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605561A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606436A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624159A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 NOV 2017 BY FB RICE

Effective date: 20140902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2018 BY CPA GLOBAL

Effective date: 20170921

LAPS Patent lapsed